Wedmont Private Capital Dexcom Inc Transaction History

Wedmont Private Capital

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 15, 2024	SELL	$110.31 - $140.45 $28,790 - $36,657	-261 Reduced 4.86%	5,107 $579,000
Q1 2024 Apr 10, 2024	BUY	$114.22 - $140.1 $49,343 - $60,523	432 Added 8.75%	5,368 $744,000
Q4 2023 Jan 09, 2024	BUY	$75.49 - $124.16 $84,699 - $139,307	1,122 Added 29.42%	4,936 $612,000
Q3 2023 Oct 10, 2023	SELL	$86.06 - $137.93 $48,796 - $78,206	-567 Reduced 12.94%	3,814 $355,000
Q2 2023 Jul 17, 2023	BUY	$112.47 - $130.98 $32,391 - $37,722	288 Added 7.04%	4,381 $563,000
Q1 2023 Apr 11, 2023	SELL	$104.0 - $122.92 $42,640 - $50,397	-410 Reduced 9.11%	4,093 $475,000
Q4 2022 Jan 09, 2023	BUY	$84.98 - $122.67 $140,556 - $202,896	1,654 Added 58.06%	4,503 $0
Q3 2022 Oct 03, 2022	BUY	$76.35 - $94.18 $217,521 - $268,318	2,849 New	2,849 $229,000
Q2 2022 Jul 11, 2022	SELL	$67.99 - $132.89 $32,295 - $63,122	-475 Closed	0 $0
Q1 2022 Apr 05, 2022	BUY	$94.08 - $130.2 $44,688 - $61,844	475 New	475 $248,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Wedmont Private Capital, based on Form 13F filings with the SEC.

Stay updated on Wedmont Private Capital with notifications on news.